These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19458290)

  • 1. Thiazolidinediones in peritoneal dialysis patients.
    Szeto CC; Chow KM
    Perit Dial Int; 2009; 29(3):248-51. PubMed ID: 19458290
    [No Abstract]   [Full Text] [Related]  

  • 2. [Peritoneal dialysis in patients with diabetes mellitus].
    Plum J
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2035-8. PubMed ID: 16143936
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of glycemia in patients with diabetes mellitus and CKD.
    Lubowsky ND; Siegel R; Pittas AG
    Am J Kidney Dis; 2007 Nov; 50(5):865-79. PubMed ID: 17954300
    [No Abstract]   [Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
    Zheng F; Guan Y
    Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
    de Boer RA; Martens FM; Kuipers I; Boomsma F; Visseren FL
    J Hum Hypertens; 2010 Jan; 24(1):74-6. PubMed ID: 19847195
    [No Abstract]   [Full Text] [Related]  

  • 7. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparisons of peritoneal transport between insulin-dependent and noninsulin-dependent and noninsulin-dependent diabetic peritoneal dialysis patients.
    Lin JJ; Wadhwa NK; Suh H; Cabralda T
    Perit Dial Int; 1997; 17(2):208-9. PubMed ID: 9159849
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.
    van Hooland S; Boey O; Van der Niepen P; Van den Branden C; Verbeelen D
    Perit Dial Int; 2009; 29(1):108-11. PubMed ID: 19164260
    [No Abstract]   [Full Text] [Related]  

  • 10. [The protective role of PPARgamma in diabetic nephropathy].
    Zang HL; Wang CJ; Yang JC
    Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):435-8. PubMed ID: 21416961
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR-gamma agonists and diabetic nephropathy.
    Zhang Y; Guan Y
    Curr Diab Rep; 2005 Dec; 5(6):470-5. PubMed ID: 16316600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR-gamma-agonists' renal effects.
    Izzedine H; Launay-Vacher V; Buhaescu I; Heurtier A; Baumelou A; Deray G
    Minerva Urol Nefrol; 2005 Dec; 57(4):247-60. PubMed ID: 16247347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'No, really, how do they work?'.
    Moore DD
    Genes Dev; 2005 Feb; 19(4):413-4. PubMed ID: 15713837
    [No Abstract]   [Full Text] [Related]  

  • 17. Pioglitazone, a PPAR-gamma ligand inhibited the nicotinamide-streptozotocin induced sperm abnormalities in type-2 diabetic Wistar rats.
    Rabbani SI; Devi K; Khanam S
    Pak J Pharm Sci; 2010 Jul; 23(3):326-31. PubMed ID: 20566448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of diabetes mellitus in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2006; 27(2):77-82. PubMed ID: 16638476
    [No Abstract]   [Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
    Thiemermann C
    Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.